Your browser doesn't support javascript.
loading
The brain microenvironment mediates resistance in luminal breast cancer to PI3K inhibition through HER3 activation.
Kodack, David P; Askoxylakis, Vasileios; Ferraro, Gino B; Sheng, Qing; Badeaux, Mark; Goel, Shom; Qi, Xiaolong; Shankaraiah, Ram; Cao, Z Alexander; Ramjiawan, Rakesh R; Bezwada, Divya; Patel, Bhushankumar; Song, Yongchul; Costa, Carlotta; Naxerova, Kamila; Wong, Christina S F; Kloepper, Jonas; Das, Rita; Tam, Angela; Tanboon, Jantima; Duda, Dan G; Miller, C Ryan; Siegel, Marni B; Anders, Carey K; Sanders, Melinda; Estrada, Monica V; Schlegel, Robert; Arteaga, Carlos L; Brachtel, Elena; Huang, Alan; Fukumura, Dai; Engelman, Jeffrey A; Jain, Rakesh K.
Affiliation
  • Kodack DP; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Askoxylakis V; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Ferraro GB; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Sheng Q; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.
  • Badeaux M; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Goel S; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Qi X; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Shankaraiah R; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Cao ZA; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.
  • Ramjiawan RR; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Bezwada D; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Patel B; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Song Y; Department of Medicine, MGH Cancer Center and HMS, Boston, MA 02129, USA.
  • Costa C; Department of Medicine, MGH Cancer Center and HMS, Boston, MA 02129, USA.
  • Naxerova K; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Wong CSF; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Kloepper J; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Das R; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.
  • Tam A; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.
  • Tanboon J; Department of Pathology, MGH and HMS, Boston, MA 02114, USA.
  • Duda DG; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Miller CR; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27514, USA.
  • Siegel MB; Department of Genetics, University of North Carolina, Chapel Hill, NC 27514, USA.
  • Anders CK; Division of Hematology Oncology, Department of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA.
  • Sanders M; Department of Pathology, Microbiology, and Immunology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37203, USA.
  • Estrada MV; Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Nashville, TN 37203, USA.
  • Schlegel R; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.
  • Arteaga CL; Departments of Medicine and Cancer Biology, Vanderbilt-Ingram Cancer Center, Nashville, TN 37203, USA.
  • Brachtel E; Department of Pathology, MGH and HMS, Boston, MA 02114, USA.
  • Huang A; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA.
  • Fukumura D; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA.
  • Engelman JA; Department of Medicine, MGH Cancer Center and HMS, Boston, MA 02129, USA. jain@steele.mgh.harvard.edu jeffrey.engelman@novartis.com.
  • Jain RK; Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA 02114, USA. jain@steele.mgh.harvard.edu jeffrey.engelman@novartis.com.
Sci Transl Med ; 9(391)2017 05 24.
Article in En | MEDLINE | ID: mdl-28539475

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Breast Neoplasms / Phosphatidylinositol 3-Kinases / Receptor, ErbB-3 Limits: Animals Language: En Journal: Sci Transl Med Journal subject: CIENCIA / MEDICINA Year: 2017 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Breast Neoplasms / Phosphatidylinositol 3-Kinases / Receptor, ErbB-3 Limits: Animals Language: En Journal: Sci Transl Med Journal subject: CIENCIA / MEDICINA Year: 2017 Document type: Article Affiliation country: